Month: January 2023
The fixed duration or time-limited treatment for chronic lymphocytic leukemia with ibrutinib (IMBRUVICA) and Venetoclax (VENCLEXTA) drug combination
The fixed duration or time-limited treatment for chronic lymphocytic leukemia patients has been an attractive option. The time-limited treatment means that patients can be observed…